Back to search results

Aloe Vera for Interstitial Cystitis Symptoms

This study is looking at whether Desert Harvest Aloe Vera Capsules can help manage the symptoms of interstitial cystitis (a chronic bladder condition causing pain and pressure). Researchers want to see if these capsules are safe and effective. You might be able to join if you are between 18 and 80 years old. The study will measure safety by tracking any side effects over 16 weeks. The current recruitment status is unclear, meaning it's not specified if they are actively enrolling participants.

Study design
This is an interventional study with 30 planned participants. You would be randomly assigned to receive either Desert Harvest Aloe Vera Capsules or a placebo (an inactive capsule), and neither you nor the study staff would know which you are receiving.
What's involved
You would be in the study for 16 weeks. The dosing of the capsules would change over the first four months.
Compensation
Not stated in the trial record.
Follow-up
The primary safety endpoint is measured at Week 16, which is the end of the study period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04734106

Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis

Recruiting
EARLY_PHASE1Ages 18–80InterventionalTreatment
Wake Forest University Health Sciences
~30 participants
Updated 2026-07-28 on ClinicalTrials.gov
What's tested:Desert Harvest Aloe Vera CapsulesPlacebo Capsules

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety, as measured by the Change in the number and severity of adverse events (AE)
Measured over Week 16

Conditions

Interstitial Cystitis
Chronic Interstitial Cystitis
Bladder Pain Syndrome

Explore related trials

Interstitial Cystitis

Where it's being run

1 sites across 1 states
North Carolina1

Study leadership

  • Stephen Walker, PhD · PRINCIPAL_INVESTIGATOR · Wake Forest Health Sciences

Who to contact

Stephen Walker, PhD
[email protected]
3367137272
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Females or males, aged 18 years or older
Females of childbearing potential must agree to use acceptable methods of birth control. Acceptable methods are oral and injectable preparations, double barrier, vasectomized partner, or abstinence.
Participant must sign and date the informed consent.
Participant must report a urinary frequency of at least 11 times per 24-hour day, on average over the previous four weeks.
Participant must report a pain/discomfort score of 4 or greater on a 0-9 Likert scale.
These reported urinary symptoms of frequency and pain/discomfort must have been present for at least the previous 24 weeks prior to the first baseline screening visit.
Participants must report in the baseline voiding diary at least one voided volume greater than or equal to 75cc in a 24-hour period.

Exclusion

Known allergy or intolerance to aloe vera in any form as reported by the participant or derived from medical records.
History of Bladder tumors (malignant or benign).
Current active bladder or urethral calculus.
History of urethral cancer within the previous five years.
Any disease which, in the opinion of the investigator, may be unstable or have bearing on the outcome of the study, including severe debilitating concurrent medical conditions such as coronary artery disease, azotemia, moderate to severe hepatic insufficiency, etc.
Previous treatment with Cytoxan (cyclophosphamide).
History of cyclophosphamide or chemical cystitis or tuberculosis or radiation cystitis.
History of pelvic radiation treatment, bladder cancer or cancer in situ, or urethral cancer.
History of any other neoplastic process currently requiring systemic, nonprophylactic treatment.
History of urethral diverticulum.
Inability to void spontaneously.
Subjects with interstitial cystitis symptoms alleviated by current therapy regimen.
Uncontrolled diabetes mellitus.
Previous enrollment in an aloe vera study.
Previous use of Desert Harvest super-concentrated, freeze-dried aloe vera capsules.
Any imminent change in residence that could compromise compliance.
Unlikely to be compliant due to unmanaged medical or psychological problem, including dementia, aphasia, or other deficits of cognition or speech/language function that will interfere with the participant's ability to complete the study.
Substance abuse or dependency problem within the past two years for which patient received no treatment.
Males with a history of prostate cancer within the previous five years.
Males with a prostatic infection within the previous three months.
Females with a history of uterine, cervical, or vaginal cancer within the previous five years.
Pregnant or lactating females.

What this trial measures

  • Safety, as measured by the Change in the number and severity of adverse events (AE)Week 16

    Non-serious adverse events will be defined as any new medical condition or worsening of an existing medical condition, not to include the disease being studied. Severe adverse events will be defined as any adverse event that results in death, a life-threatening event, inpatient hospitalization, prolongation of existing hospitalization (hospitalization for an elective treatment of a pre-existing condition will not be considered a serious event), disability or incapacity, or an important medical event, which, though not included previously, may jeopardize the participant and may require medical or surgical intervention.